Ensysce Biosciences Inc. (ENSC)
| Bid | 1.86 |
| Market Cap | 3.22M |
| Revenue (ttm) | 487.52K |
| Net Income (ttm) | -7.99M |
| EPS (ttm) | -11.45 |
| PE Ratio (ttm) | -0.16 |
| Forward PE | -0.7 |
| Analyst | n/a |
| Ask | 1.92 |
| Volume | 43,854 |
| Avg. Volume (20D) | 40,688 |
| Open | 2.11 |
| Previous Close | 2.03 |
| Day's Range | 1.87 - 2.11 |
| 52-Week Range | 1.70 - 14.67 |
| Beta | 1.07 |
About ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF...
1 month ago · accessnewswire.com
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial ResultsSecures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / ...
1 month ago · accessnewswire.com
Ensysce Biosciences to Participate in the 37th Annual ROTH ConferenceSAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for seve...
2 months ago · accessnewswire.com
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or...